Appropriate, timely, and rational treatment of type 2 diabetes mellitus: Meeting the challenges of primary care

Insulin

Volumn 4, Issue 3, 2009, Pages 144-157

  Unger, Jeff ^a   Parkin, Christopher G ^b  

^a Catalina Research Institute California   (United States)

^b CGParkin Communications Inc   (United States)

Author keywords

diabetes; impaired fasting glucose; impaired glucose tolerance; pharmacotherapy; prediabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV; EXENDIN 4; FATTY ACID; GLUCAGON LIKE PEPTIDE 1; INCRETIN; INSULIN; INSULIN DERIVATIVE; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; PLACEBO; PRAMLINTIDE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE;

ADD ON THERAPY; ARTICLE; BEHAVIOR MODIFICATION; BLOOD GLUCOSE MONITORING; BODY WEIGHT; CLINICAL DECISION MAKING; CLINICAL TRIAL; DIABETES CONTROL; DIABETES EDUCATION; DIABETIC RETINOPATHY; EARLY INTERVENTION; EXERCISE; GLYCEMIC CONTROL; HUMAN; HYPERGLUCAGONEMIA; HYPERINSULINEMIA; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PHYSICAL ACTIVITY; PREVALENCE; PRIMARY MEDICAL CARE; RISK REDUCTION; SELF MONITORING; SIDE EFFECT; UNITED STATES;

EID: 68749118736     PISSN: 15570843     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1557-0843(09)80029-8     Document Type: Article

References (99)

1. Garber A.J., Handelsman Y., Einhorn D., et al. Diagnosis and management of prediabetes in the continuum of hyperglycemia: When do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract. 14 (2008) 933-946
2. Centers for Disease Control and Prevention (CDC). 2007 National diabetes fact sheet: General information and national estimates on diabetes in the United States, 2007. Atlanta, Ga: US Department of Health and Human Services, Centers for Disease Control and Prevention 2008. http://www.cdc.gov/diabetes/pubs/factsheet07.htm Accessed May 22, 2009
3. Phillips L.S., Branch W.T., Cook C.B., et al. Clinical inertia. Ann Intern Med. 135 (2001) 825-834
4. Ziemer D.C., Miller C.D., Rhee M.K., et al. Clinical inertia contributes to poor diabetes control in a primary care setting. Diabetes Educ. 31 (2005) 564-571
5. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 329 (1993) 977-986
6. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 44 (1995) 968-983
7. Ohkubo Y., Kishikawa H., Araki E., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract. 28 (1995) 103-117
8. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 DM (UKPDS 33) [published correction appears in Lancet. 199;354:602]. Lancet 352 (1998) 837-853
9. Gerstein H.C., Miller M.E., Byington R.P., et al., Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 358 (2008) 2545-2559
10. Patel A., MacMahon S., Chalmers J., et al., ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 358 (2008) 2560-2572
11. Coutinho M., Gerstein H.C., Wang Y., and Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 22 (1999) 233-240
12. Stettler C., Allemann S., Jüni P., et al. Glycemic control and mac-rovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials. Am Heart J. 152 (2006) 27-38
13. Anselmino M., Ohrvik J., Malmberg K., et al., the Euro Heart Survey Investigators. Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: A report from the Euro Heart Survey on Diabetes and the Heart. Eur Heart J. 29 (2008) 177-184
14. Nathan D.M., Cleary P.A., Backlund J.Y., et al., the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 353 (2005) 2643-2653
15. Stratton I.M., Adler A.I., Neil H.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 321 (2000) 405-412
16. Holman R.R., Paul S.K., Bethel M.A., et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 359 (2008) 1577-1589
17. Monnier L., Colette C., Dunseath G.J., and Owens D.R. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 30 (2007) 263-269
18. Rodriguez B.L., Curb J.D., Burchfiel C.M., et al. Impaired glucose tolerance, diabetes, and cardiovascular disease risk factor profiles in the elderly. The Honolulu Heart Program. Diabetes Care 19 (1996) 587-590
19. Diabetes Prevention Program Research Group. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabetes Med. 24 (2007) 137-144
20. Sumner C.J., Sheth S., Griffin J.W., et al. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology 60 (2003) 108-111
21. Knowler W.C., Barrett-Connor E., Fowler S.E., et al., the Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 346 (2002) 393-403
22. Tuomilehto J., Lindström J., Eriksson J.G., et al., the Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 344 (2001) 1343-1350
23. Buchanan T.A., Xiang A.H., Peters R.K., et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 51 (2002) 2796-2803
24. Gerstein H.C., Yusuf S., Bosch J., et al., the DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial [published correction appears in Lancet. 2006;368:1770]. Lancet 368 (2006) 1096-1105
25. Chiasson J.L., Josse R.G., Gomis R., et al., the STOP-NIDDM Trial Research Group. Acarbose for the prevention of type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: Facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data. Diabetologia. 47 (2004) 969-975 discussions 976-977
26. Aronoff S.L., Berkowitz K., Shreiner B., and Want L. Glucose metabolism and regulation: Beyond insulin and glucagon. Diabetes Spectrum. 17 (2004) 183-190
27. Ferrannini E. Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: Problems and prospects. Endocr Rev. 19 (1998) 477-490
28. Unger J., and Moriarty C. Preventing type 2 diabetes. Prim Care 35 (2008) 645-662
29. Butler A.E., Janson J., Bonner-Weir S., et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52 (2003) 102-110
30. Unger R.H. Glucagon physiology and pathophysiology in the light of new advances. Diabetologia. 28 (1985) 574-578
31. Unger J. Diabetes Management in Primary Care (2007), Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia, Pa 618-645
32. Shimomura I., Matsuda M., Hammer R.E., et al. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell. 6 (2000) 77-86
33. Unger R.H. Reinventing type 2 diabetes: Pathogenesis, treatment, and prevention. JAMA. 299 (2008) 1185-1187
34. Lee Y., Hirose H., Ohneda M., et al. Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: Impairment in adipocyte-beta-cell relationships. Proc Natl Acad Sci U S A. 91 (1994) 10878-10882
35. Holst J.J., and Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab. 287 (2004) E199-E206
36. Toft-Nielsen M.B., Damholt M.B., Madsbad S., et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab. 86 (2001) 3717-3723
37. Mojsov S., Weir G.C., and Habener J.F. Insulinotropin: Glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest. 79 (1987) 616-619
38. Göke R., Wagner B., Fehmann H.C., and Göke B. Glucose-dependency of the insulin stimulatory effect of glucagon-like peptide-1 (7-36) amide on the rat pancreas. Res Exp Med (Berl). 193 (1993) 97-103
39. Holst J.J. Glucagon-like peptide 1 (GLP-1): An intestinal hormone, signalling nutritional abundance, with an unusual therapeutic potential. Trends Endocrinol Metab. 10 (1999) 229-235
40. Willms B., Werner J., Holst J.J., et al. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: Effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab. 81 (1996) 327-332
41. Young A.A., Gedulin B.R., and Rink T.J. Dose-responses for the slowing of gastric emptying in a rodent model by glucagon-like peptide (7-36) NH2, amylin, cholecystokinin, and other possible regulators of nutrient uptake. Metabolism. 45 (1996) 1-3
42. Turton M.D., O'Shea D., Gunn I., et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379 (1996) 69-72
43. Kendall D.M., Riddle M.C., Rosenstock J., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 28 (2005) 1083-1091
44. Vilsboell T., Zdravkovic M., and Le-Thi T. Liraglutide significantly improves glycemic control, and lowers body weight without risk of either major or minor hypoglycemic episodes in subjects with type 2 diabetes. Presented at: 66th Annual Meeting of the America Diabetes Association. Washington, DC (June 9-13, 2006)
45. Li Y., Hansotia T., Yusta B., et al. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem. 278 (2003) 471-478
46. Gaede P., Lund-Andersen H., Parving H.H., and Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 358 (2008) 580-591
47. Gaede P., Valentine W.J., Palmer A.J., et al. Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: Results and projections from the Steno-2 study. Diabetes Care 31 (2008) 1510-1515
48. UK Prospective Diabetes Study (UKPDS) Group. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. BMJ. 317 (1998) 720-726
49. UK Prospective Diabetes Study (UKPDS) Group. UKPDS 28: A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. Diabetes Care. 21 (1998) 87-92
50. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) [published correction appears in Lancet. 1998;352:1558]. Lancet 352 (1998) 854-865
51. UK Prospective Diabetes Study (UKPDS) Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 317 (1998) 713-720
52. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 DM: UKPDS 38 [published correction appears in BMJ. 1999;318:29]. BMJ. 317 (1998) 703-713
53. International Diabetes Federation (IDF). Guideline for management of postmeal glucose (2007). http://www.idf.org/webdata/docs/Guideline_PMG_final.pdf Accessed May 22, 2009
54. Sorkin J.D., Muller D.C., Fleg J.L., and Andres R. The relation of fasting and 2-h postchallenge plasma glucose concentrations to mortality: Data from the Baltimore Longitudinal Study of Aging with a critical review of the literature. Diabetes Care 28 (2005) 2626-2632
55. Levitan E.B., Song Y., Ford E.S., and Liu S. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med. 164 (2004) 2147-2155
56. Cavalot F., Petrelli A., Traversa M., et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: Lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab. 91 (2006) 813-819
57. Ceriello A., Quagliaro L., Piconi L., et al. Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes 53 (2004) 701-710
58. Hanefeld M., Koehler C., Schaper F., et al. Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals. Atherosclerosis 144 (1999) 229-235
59. Williams S.B., Goldfine A.B., Timimi F.K., et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 97 (1998) 1695-1701
60. Kawano H., Motoyama T., Hirashima O., et al. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol. 34 (1999) 146-154
61. Gaudet-Savard T., Ferland A., Broderick T.L., et al. Safety and magnitude of changes in blood glucose levels following exercise performed in the fasted and the postprandial state in men with type 2 diabetes. Eur J Cardiovasc Prev Rehabil. 14 (2007) 831-836
62. Galbo H., Tobin L., and van Loon L.J. Responses to acute exercise in type 2 diabetes, with an emphasis on metabolism and interaction with oral hypoglycemic agents and food intake. Appl Physiol Nutr Metab. 32 (2007) 567-575
63. Burani J., and Longo P.J. Low-glycemic index carbohydrates: An effective behavioral change for glycemic control and weight management in patients with type 1 and 2 diabetes. Diabetes Educ. 32 (2006) 78-88
64. Clark C.A., Gardiner J., McBurney M.I., et al. Effects of breakfast meal composition on second meal metabolic responses in adults with Type 2 diabetes mellitus. Eur J Clin Nutr. 60 (2006) 1122-1129
65. Turner R., Cull C., and Holman R. United Kingdom Prospective Diabetes Study 17: A 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med. 124 (1996) 136-145
66. Uusitupa M., Lindi V., Louheranta A., et al. Long-term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance: 4-Year results from the Finnish Diabetes Prevention Study. Diabetes 52 (2003) 2532-2538
67. O'Keefe J.H., Gheewala N.M., and O'Keefe J.O. Dietary strategies for improving post-prandial glucose, lipids, inflammation, and cardiovascular health. J Am Coll Cardiol. 51 (2008) 249-255
68. Duncan G.E., Perri M.G., Theriaque D.W., et al. Exercise training, without weight loss, increases insulin sensitivity and postheparin plasma lipase activity in previously sedentary adults. Diabetes Care 26 (2003) 557-562
69. Poirier P., Tremblay A., Catellier C., et al. Impact of time interval from the last meal on glucose response to exercise in subjects with type 2 diabetes. J Clin Endocrinol Metab. 85 (2000) 2860-2864
70. Rodbard H.W., Blonde L., Braithwaite S.S., et al., the AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus [published correction appears in Endocr Pract. 2008;14:802-803]. Endocr Pract. 13 Suppl 1 (2007) 1-68
71. Unger J. Reducing oxidative stress in patients with type 2 diabetes mellitus: A primary care call to action. Insulin 3 (2008) 176-184
72. Stonehouse A., Okerson T., Kendall D., and Maggs D. Emerging incretin based therapies for type 2 diabetes: Incretin mimetics and DPP-4 inhibitors. Curr Diabetes Rev. 4 (2008) 101-109
73. Blonde L., Klein E.J., Han J., et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab. 8 (2006) 436-447
74. Klonoff D.C., Buse J.B., Nielsen L.L., et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomark-ers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 24 (2008) 275-286
75. Garber A., Henry R., Ratner R., et al., the LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): A randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373 (2009) 473-481
76. Blonde L., Rosenstock J., Sesti G., et al. Liraglutide: Superior glycemic control vs exenatide when added to metformin and/or SU in type 2 diabetes mellitus. Can J Diabetes 32 Suppl (2008) A107
77. Herman G.A., Stevens C., Van Dyck K., et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther. 78 (2005) 675-688
78. Mu J., Woods J., Zhou Y.P., et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 55 (2006) 1695-1704
79. Amori R.E., Lau J., and Pittas A.G. Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis. JAMA 298 (2007) 194-206
80. DeFronzo R.A., Okerson T., Viswanathan P., et al. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: A randomized, cross-over study. Curr Med Res Opin. 24 (2008) 2943-2952
81. Nathan D.M., Buse J.B., Davidson M.B., et al. Management of hyper-glycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes [published correction appears in Diabetes Care. 2006;49:2816-2818]. Diabetes Care 29 (2006) 1963-1972
82. American Diabetes Association. 55th Annual Advanced Postgraduate Course (2008) (February 1-3, 2008). http://www.professional.diabetes.org/Congress_Display.aspx?TYP=9&CID =57416 Accessed May 24, 2009
83. Nagi D.K., and Yudkin J.S. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care 16 (1993) 621-629
84. DeFronzo R.A., Goodman A.M., and the Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 333 (1995) 541-549
85. Grant P.J. The effects of metformin on the fibrinolytic system in diabetic and non-diabetic subjects. Diabete Metab. 17 (1991) 168-173
86. Chu N.V., Kong A.P., Kim D.D., et al. Differential effects of met- formin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care 25 (2002) 542-549
87. Johnson J.A., Majumdar S.R., Simpson S.H., and Toth E.L. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 25 (2002) 2244-2248
88. Ortiz D.D. Using a simple patient registry to improve your chronic disease care. Fam Pract Manag. 13 (2006) 42-47
89. Standards of medical care in diabetes-2009. Diabetes Care 32 Suppl 1 (2009) S13-S61
90. Hammer M.J., Casper C., Gooley T.A., et al. The contribution of malglycemia to mortality among allogeneic hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 15 (2009) 344-351
91. Monnier L., Lapinski H., and Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: Variations with increasing levels of HbA(1c). Diabetes Care 26 (2003) 881-885
92. Parkin C.G., and Davidson J.A. Value of self-monitoring of blood glucose pattern analysis in improving diabetes outcomes. J Diabetes Sci Technol. 3 (2009) 500-508
93. Parkin C.G., and Brooks N. Is postprandial glucose control important? Is it practical in primary care settings?. Clin Diabetes 20 (2002) 71-76
94. Dailey G. Assessing glycemic control with self-monitoring of blood glucose and hemoglobin A(1c) measurements. Mayo Clin Proc. 82 (2007) 229-235 quiz 206
95. Jellinger P.S., Davidson J.A., Blonde L., et al., the ACE/AACE Diabetes Road Map Task Force. Road maps to achieve glycemic control in type 2 diabetes mellitus. Endocr Pract. 13 (2007) 260-268
96. Bailey T.S., Zisser H.C., and Garg S.K. Reduction in hemoglobin A1C with real-time continuous glucose monitoring: Results from a 12-week observational study. Diabetes Technol Ther. 9 (2007) 203-210
97. Allen N.A., Fain J.A., Braun B., and Chipkin S.R. Continuous glucose monitoring in non-insulin-using individuals with type 2 diabetes: Acceptability, feasibility, and teaching opportunities. Diabetes Technol Ther. 11 (2009) 151-158
98. Ceriello A., Garber A., and Hirsch I.B. Postprandial glycemic control. Achieving goals in type 2 diabetes. Medical Crossfire. 6 (2005) 4-18
99. Beebe C.A. Self blood glucose monitoring: An adjunct to dietary and insulin management of the patient with diabetes. J Am Diet Assoc. 87 (1987) 61-65